Contact
Please use this form to send email to PR contact of this press release:
Aurealis Therapeutics DIAMEND Phase-2 RCT: AUP-16 Tripling Complete Wound Closure Rate in Patients with Chronic DFU
TO:
Laurent DECORY
Aurealis Therapeutics